Commentary
Podcast
This episode provides a brief overview of California's new Stop Dangerous Pharmacies Act, the benefits of e-prescribing for improving patient safety and outcomes, and New Jersey's pilot program for anonymous dispensing of opioid antidotes from pharmacies.
0:01:02 - Discussion of California's Stop Dangerous Pharmacies Act
0:01:56 - Discussion of benefits of e-prescribing and challenges
0:02:08 - Discussion of New Jersey's pilot program for anonymous dispensing of opioid antidotes from pharmacies
In this episode, we discuss 3 new pharmacy policies and initiatives across the United States as part of a new "RX rundown" format. First, California enacted the Stop Dangerous Pharmacies Act to improve patient safety through mandatory error reporting, minimum staffing, and expanded technician roles. Then, E-prescribing was discussed as a way to enhance accuracy, safety, and reduce costs and errors, though national standards and privacy issues present challenges. Lastly, New Jersey is piloting anonymous dispensing of opioid antidotes from pharmacies under standing orders from health officials to help address the opioid crisis, with pharmacist education requirements.
Key Takeaways:
1. California enacted the Stop Dangerous Pharmacies Act to mandate medication error reporting, minimum staffing requirements, and expand pharmacy technician roles like administering vaccines.
2. E-prescribing can improve accuracy, safety, and reduce costs by reducing errors and combating forged prescriptions while improving pharmacy workflow. However, it faces challenges around national standards and security/privacy.
3. New Jersey launched a pilot program allowing anonymous dispensing of opioid antidotes from pharmacies with standing orders from health officials, and pharmacists must provide overdose prevention education.
FDA Approves Ustekinumab-kfce as Sixth Biosimilar to Stelara
